Catherine C Davis
Overview
Explore the profile of Catherine C Davis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
3048
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Davis C, Miller K, Peterson J
Front Reprod Health
. 2024 Jan;
5:1339278.
PMID: 38250172
No abstract available.
2.
Friberg M, Woeller K, Iberi V, Mancheno P, Riedeman J, Bohman L, et al.
Front Reprod Health
. 2023 Sep;
5:1162746.
PMID: 37671283
Introduction: Menstrual cups (MC) are a reusable feminine hygiene product. A recent publication suggested that () biofilms can form on MCs which may lead to increased risk of menstrual Toxic...
3.
Schlievert P, Davis C
Clin Microbiol Rev
. 2020 May;
33(3).
PMID: 32461307
In the 1980s, menstrual toxic shock syndrome (mTSS) became a household topic, particularly among mothers and their daughters. The research performed at the time, and for the first time, exposed...
4.
Pierson J, Hansmann M, Davis C, Forney L
Pathog Dis
. 2018 May;
76(4).
PMID: 29762733
Menstrual toxic shock syndrome is associated with vaginal colonization by Staphylococcus aureus strains that encode toxic shock syndrome toxin 1 (tst+). Interestingly, a small proportion of women are colonized by...
5.
Davis C, Baccam M, Mantz M, Osborn T, Hill D, Squier C
Toxicol Appl Pharmacol
. 2013 Dec;
274(2):240-8.
PMID: 24333258
Menstrual toxic shock syndrome (mTSS) is a rare, recognizable, and treatable disease that has been associated with tampon use epidemiologically. It involves a confluence of microbial risk factors (Staphylococcus aureus...
6.
Hirji I, Gupta S, Goren A, Chirovsky D, Moadel A, Olavarria E, et al.
Health Qual Life Outcomes
. 2013 Oct;
11:167.
PMID: 24099272
Background: The availability of the tyrosine-kinase inhibitor (TKI), imatinib, and later introduction of second generation TKIs, dasatinib and nilotinib, have not only improved clinical outcomes of patients with chronic myeloid...
7.
Kimber I, Nookala S, Davis C, Gerberick G, Tucker H, Foertsch L, et al.
Toxicol Sci
. 2013 May;
134(1):49-63.
PMID: 23640863
Noninvasive vaginal infections by Staphylococcus aureus strains producing the superantigen TSST-1 can cause menstrual toxic shock syndrome (mTSS). With the objective of exploring the basis for differential susceptibility to mTSS,...
8.
Davis C, Claudius M, Palinkas L, Wong J, Leslie L
J Atten Disord
. 2011 Oct;
16(8):675-84.
PMID: 21976032
Objective: To examine components of family-centered care in families' stories about treatment decision making for their child with ADHD. Method: Twenty-eight families participated in qualitative interviews that addressed families' perspectives...
9.
Ravel J, Gajer P, Abdo Z, Schneider G, Koenig S, McCulle S, et al.
Proc Natl Acad Sci U S A
. 2010 Jun;
108 Suppl 1:4680-7.
PMID: 20534435
The means by which vaginal microbiomes help prevent urogenital diseases in women and maintain health are poorly understood. To gain insight into this, the vaginal bacterial communities of 396 asymptomatic...
10.
Schlievert P, Nemeth K, Davis C, Peterson M, Jones B
Clin Vaccine Immunol
. 2010 Mar;
17(5):722-7.
PMID: 20335433
Staphylococcal toxic shock syndrome toxin 1 (TSST-1) is the cause of menstrual toxic shock syndrome (mTSS) associated with vaginal colonization by Staphylococcus aureus. In this pilot study, we measured TSST-1...